Hubbry Logo
Benign tumorBenign tumorMain
Open search
Benign tumor
Community hub
Benign tumor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Benign tumor
Benign tumor
Benign tumor
View on Wikipedia
from Wikipedia
Benign tumor
Other namesnon-cancerous tumor
Normal epidermis and dermis with intradermal nevus, 10x-cropped
SpecialtyOncology, Pathology

A benign tumor is a mass of cells (tumor) that does not invade neighboring tissue or metastasize (spread throughout the body). Compared to malignant (cancerous) tumors, benign tumors generally have a slower growth rate. Benign tumors have relatively well differentiated cells. They are often surrounded by an outer surface (fibrous sheath of connective tissue) or stay contained within the epithelium. Common examples of benign tumors include moles and uterine fibroids.

Some forms of benign tumors may be harmful to health. Benign tumor growth causes a mass effect that can compress neighboring tissues. This can lead to nerve damage, blood flow reduction (ischemia), tissue death (necrosis), or organ damage. The health effects of benign tumor growth may be more prominent if the tumor is contained within an enclosed space such as the cranium, respiratory tract, sinus, or bones. For example, unlike most benign tumors elsewhere in the body, benign brain tumors can be life-threatening. Tumors may exhibit behaviors characteristic of their cell type of origin; as an example, endocrine tumors such as thyroid adenomas and adrenocortical adenomas may overproduce certain hormones.

The word benign means 'favourable, kind, fortunate, salutary, propitious'.[1] However, a benign tumor is not benign in the usual sense; the name merely specifies that it is not "malignant", i.e. cancerous. While benign tumors usually do not pose a serious health risk, they can be harmful or fatal.[2] Many types of benign tumors have the potential to become cancerous (malignant) through a process known as tumor progression. For this reason and other possible harms, some benign tumors are removed by surgery. When removed, benign tumors usually do not return. Exceptions to this rule may indicate malignant transformation.

Signs and symptoms

[edit]

Benign tumors are very diverse; they may be asymptomatic or may cause specific symptoms, depending on their anatomic location and tissue type. They grow outward, producing large, rounded masses which can cause what is known as a "mass effect". This growth can cause compression of local tissues or organs, leading to many effects, such as blockage of ducts, reduced blood flow (ischaemia), tissue death (necrosis) and nerve pain or damage.[3] Some tumors also produce hormones that can lead to life-threatening situations. Insulinomas can produce large amounts of insulin, causing hypoglycemia.[4][5] Pituitary adenomas can cause elevated levels of hormones such as growth hormone and insulin-like growth factor-1, which cause acromegaly; prolactin; ACTH and cortisol, which cause Cushing's disease; TSH, which causes hyperthyroidism; and FSH and LH.[6] Bowel intussusception can occur with various benign colonic tumors.[7] Cosmetic effects can be caused by tumors, especially those of the skin, possibly causing psychological or social discomfort for the person with the tumor.[8] Vascular tissue tumors can bleed, in some cases leading to anemia.[9]

Causes

[edit]

PTEN hamartoma syndrome

[edit]

PTEN hamartoma syndrome encompasses hamartomatous disorders characterized by genetic mutations in the PTEN tumor suppressor gene,[10] including Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome, Proteus syndrome and Proteus-like syndrome. Absent or dysfunctional PTEN protein allows cells to over-proliferate, causing hamartomas.[11] Cowden syndrome is an autosomal dominant genetic disorder characterized by multiple benign hamartomas (trichilemmomas and mucocutaneous papillomatous papules) as well as a predisposition for cancers of multiple organs including the breast and thyroid.[12][13] Bannayan–Riley–Ruvalcaba syndrome is a congenital disorder characterized by hamartomatous intestinal polyposis, macrocephaly, lipomatosis, hemangiomatosis and glans penis macules.[11][14] Proteus syndrome is characterized by nevi, asymmetric overgrowth of various body parts, adipose tissue dysregulation, cystadenomas, adenomas, vascular malformation.[15][16]

Endoscopic image of sigmoid colon of a patient with familial adenomatous polyposis.

Familial adenomatous polyposis

[edit]

Familial adenomatous polyposis (FAP) is a familial cancer syndrome caused by mutations in the APC gene. In FAP, adenomatous polyps are present in the colon. The polyps progress into colon cancer unless removed.[17] The APC gene is a tumor suppressor. Its protein product is involved in many cellular processes. Inactivation of the APC gene leads to the buildup of a protein called β-catenin. This protein activates two transcription factors: T-cell factor (TCF) and lymphoid enhancer factor (LEF). These factors cause the upregulation of many genes involved in cell proliferation, differentiation, migration and apoptosis (programmed cell death), causing the growth of benign tumors.[18]

Tuberous sclerosis complex

[edit]

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in the genes TSC1 and TSC2. TSC1 produces the protein hamartin. TSC2 produces the protein tuberin. This disorder presents with many benign hamartomatous tumors including angiofibromas, renal angiomyolipomas, and pulmonary lymphangiomyomatosis. Tuberin and hamartin inhibit the mTOR protein in normal cellular physiology. Inactivation of the TSC tumor suppressors causes an increase in mTOR activity. This leads to the activation of genes and the production of proteins that increase cell growth.[19][20][21]

Von Hippel–Lindau disease

[edit]

Von Hippel–Lindau disease is a dominantly inherited cancer syndrome that significantly increases the risk of various tumors. This includes benign hemangioblastomas and malignant pheochromocytomas, renal cell carcinomas, pancreatic endocrine tumors, and endolymphatic sac tumors. It is caused by genetic mutations in the Von Hippel–Lindau tumor suppressor gene. The VHL protein (pVHL) is involved in cellular signaling in oxygen starved (hypoxic) cells. One role of pVHL is to cause the cellular degradation of another protein, HIF1α. Dysfunctional pVHL leads to accumulation of HIF1α. This activates several genes responsible for the production of substances involved in cell growth and blood vessel production: VEGF, PDGFβ, TGFα and erythropoietin.[22]

Bone tumors

[edit]

Benign tumors of bone can be similar macroscopically and require a combination of a clinical history with cytogenetic, molecular, and radiologic tests for diagnosis.[23] Three common forms of benign bone tumors with are giant cell tumor of bone, osteochondroma, and enchondroma; other forms of benign bone tumors exist but may be less prevalent.[citation needed]

Giant cell tumors

[edit]

Giant cell tumors of bone frequently occur in long bone epiphyses of the appendicular skeleton or the sacrum of the axial skeleton. Local growth can cause destruction of neighboring cortical bone and soft tissue, leading to pain and limiting range of motion. The characteristic radiologic finding of giant cell tumors of bone is a lytic lesion that does not have marginal sclerosis of bone. On histology, giant cells of fused osteoclasts are seen as a response to neoplastic mononucleated cells. Notably, giant cells are not unique among benign bone tumors to giant cell tumors of bone. Molecular characteristics of the neoplastic cells causing giant cell tumors of bone indicate an origin of pluripotent mesenchymal stem cells that adopt preosteoblastic markers. Cytogenetic causes of giant cell tumors of bone involve telomeres. Treatment involves surgical curettage with adjuvant bisphosphonates.[citation needed]

Osteochondroma

[edit]

Osteochondromas form cartilage-capped projections of bone. Structures such as the marrow cavity and cortical bone of the osteochondroma are contiguous to those of the originating bone. Sites of origin often involve metaphyses of long bones. While many osteochondromas occur spontaneously, there are cases in which several osteochondromas can occur in the same individual; these may be linked to a genetic condition known as hereditary multiple osteochondromas. Osteochondroma appears on X-ray as a projecting mass that often points away from joints.[23] These tumors stop growing with the closure of the parental bone's growth plates. Failure to stop growth can be indicative of transformation to malignant chondrosarcoma. Treatment is not indicated unless symptomatic. In that case, surgical excision is often curative.[citation needed]

Enchondroma

[edit]

Enchondromas are benign tumors of hyaline cartilage. Within a bone, enchondromas are often found in metaphyses. They can be found in many types of bone, including small bones, long bones, and the axial skeleton. X-ray of enchondromas shows well-defined borders and a stippled appearance.[23] Presentation of multiple enchondromas is consistent with multiple enchondromatosis (Ollier Disease). Treatment of enchondromas involves surgical curettage and grafting.[citation needed]

Benign soft tissue tumors

[edit]

Lipomas

[edit]

Lipomas are benign, subcutaneous tumors of fat cells (adipocytes). They are usually painless, slow-growing, and mobile masses that can occur anywhere in the body where there are fat cells, but are typically found on the trunk and upper extremities.[24]

[25] Although lipomas can develop at any age, they more commonly appear between the ages of 40 and 60.[24] Lipomas affect about 1% of the population, with no documented sex bias, and about 1 in every 1000 people will have a lipoma within their lifetime.[25][26] The cause of lipomas is not well defined. Genetic or inherited causes of lipomas play a role in around 2-3% of patients.[25] In individuals with inherited familial syndromes such as Proteus syndrome or Familial multiple lipomatosis, it is common to see multiple lipomas across the body.[25] These syndromes are also associated with specific symptoms and sub-populations. Mutations in chromosome 12 have been identified in around 65% of lipoma cases.[25] Lipomas have also been shown to be increased in those with obesity, hyperlipidemia, and diabetes mellitus.[25]

Lipomas are usually diagnosed clinically, although imaging (ultrasound, computed tomography, or magnetic resonance imaging) may be utilized to assist with the diagnosis of lipomas in atypical locations.[24] The main treatment for lipomas is surgical excision, after which the tumor is examined with histopathology to confirm the diagnosis.[24] The prognosis for benign lipomas is excellent and recurrence after excision is rare, but may occur if the removal was incomplete.[25]

Mechanism

[edit]
Benign (L) vs Malignant tumor (R).

Benign vs malignant

[edit]
Diagram showing two epithelial tumors. The upper tumor is a benign tumor that is non-invasive. Benign tumors are usually round in shape and encapsulated by fibrous connective tissue. The lower picture depicts a malignant tumor. It is irregularly shaped, vascular, and it is invasive, crossing the basement membrane.

One of the most important factors in classifying a tumor as benign or malignant is its invasive potential. If a tumor lacks the ability to invade adjacent tissues or spread to distant sites by metastasizing then it is benign, whereas invasive or metastatic tumors are malignant.[3] For this reason, benign tumors are not classed as cancer.[27] Benign tumors will grow in a contained area usually encapsulated in a fibrous connective tissue capsule. The growth rates of benign and malignant tumors also differ; benign tumors generally grow more slowly than malignant tumors. Although benign tumors pose a lower health risk than malignant tumors, they both can be life-threatening in certain situations. There are many general characteristics which apply to either benign or malignant tumors, but sometimes one type may show characteristics of the other. For example, benign tumors are mostly well differentiated and malignant tumors are often undifferentiated. However, undifferentiated benign tumors and differentiated malignant tumors can occur.[28][29] Although benign tumors generally grow slowly, cases of fast-growing benign tumors have also been documented.[30] Some malignant tumors are mostly non-metastatic such as in the case of basal-cell carcinoma.[31] CT and chest radiography can be a useful diagnostic exam in visualizing a benign tumor and differentiating it from a malignant tumor. The smaller the tumor on a radiograph, the more likely it is to be benign as 80% of lung nodules less than 2 cm in diameter are benign. Most benign nodules are smoothed radiopaque densities with clear margins but these are not exclusive signs of benign tumors.[32]

Multistage carcinogenesis

[edit]

Tumors are formed by carcinogenesis, a process in which cellular alterations lead to the formation of cancer. Multistage carcinogenesis involves the sequential genetic or epigenetic changes to a cell's DNA, where each step produces a more advanced tumor. It is often broken down into three stages; initiation, promotion and progression, and several mutations may occur at each stage. Initiation is where the first genetic mutation occurs in a cell. Promotion is the clonal expansion (repeated division) of this transformed cell into a visible tumor that is usually benign. Following promotion, progression may take place where more genetic mutations are acquired in a sub-population of tumor cells. Progression changes the benign tumor into a malignant tumor.[33][34] A prominent and well studied example of this phenomenon is the tubular adenoma, a common type of colon polyp which is an important precursor to colon cancer. The cells in tubular adenomas, like most tumors that frequently progress to cancer, show certain abnormalities of cell maturation and appearance collectively known as dysplasia. These cellular abnormalities are not seen in benign tumors that rarely or never turn cancerous, but are seen in other pre-cancerous tissue abnormalities which do not form discrete masses, such as pre-cancerous lesions of the uterine cervix.[citation needed]

Diagnosis

[edit]

Classification

[edit]
Tumors and cell origin
Cell origin Cell type Tumor
Endodermal Biliary tree Cholangioma
Colon Colonic polyp
Glandular Adenoma
Papilloma
Cystadenoma
Liver Liver cell adenoma
Placental Hydatiform mole
Renal Renal tubular adenoma
Squamous Squamous cell papilloma
Stomach Gastric polyp
Mesenchymal Blood vessel Hemangioma, Cardiac myxoma
Bone Osteoma
Cartilage Chondroma
Fat tissue Lipoma
Fibrous tissue Fibroma
Lymphatic vessel Lymphangioma
Smooth muscle Leiomyoma
Striated muscle Rhabdomyoma
Ectodermal Glia Astrocytoma, Schwannoma
Melanocytes Nevus
Meninges Meningioma
Nerve cells Ganglioneuroma
Reference[35]

Benign neoplasms are typically, but not always, composed of cells which bear a strong resemblance to a normal cell type in their organ of origin. These tumors are named for the cell or tissue type from which they originate. The suffix "-oma" (but not -carcinoma, -sarcoma, or -blastoma, which are generally cancers) is applied to indicate a benign tumor. For example, a lipoma is a common benign tumor of fat cells (lipocytes), and a chondroma is a benign tumor of cartilage-forming cells (chondrocytes). Adenomas are benign tumors of gland-forming cells, and are usually specified further by their cell or organ of origin, as in hepatic adenoma (a benign tumor of hepatocytes, or liver cells). Teratomas contain many cell types such as skin, nerve, brain and thyroid, among others, because they are derived from germ cells.[36] Hamartomas are a group of benign tumors that have relatively normal cellular differentiation but exhibit disorganized tissue organization.[19]

Exceptions to the nomenclature rules exist for historical reasons; malignant examples include melanoma (a cancer of pigmented skin cells, or melanocytes) and seminoma (a cancer of male reproductive cells).[37]

Benign tumors do not encompass all benign growths. Skin tags, vocal chord polyps, and hyperplastic polyps of the colon are often referred to as benign, but they are overgrowths of normal tissue rather than neoplasms.[36]

Treatment

[edit]

Benign tumors typically need no treatment unless they cause problems such as seizures, discomfort or cosmetic concerns. Surgery is usually the most effective approach and is used to treat most benign tumors. In some cases, other treatments may be used. Adenomas of the rectum may be treated with sclerotherapy, in which chemicals are used to shrink blood vessels in order to cut off the blood supply.[38] Most benign tumors do not respond to chemotherapy or radiation therapy, although there are exceptions; benign intercranial tumors are sometimes treated with radiation therapy and chemotherapy under certain circumstances.[39][40] Radiation can also be used to treat hemangiomas in the rectum.[38] Benign skin tumors are usually surgically resected but other treatments such as cryotherapy, curettage, electrodesiccation, laser therapy, dermabrasion, chemical peels and topical medication are used.[41][42]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Benign tumor

View on Grokipedia
from Grokipedia
A benign tumor is a noncancerous growth of cells that forms a mass but does not invade nearby tissues or spread to other parts of the body. Unlike malignant tumors, which are cancerous and capable of , benign tumors remain localized and grow slowly, often encapsulated by a fibrous capsule that limits their expansion. These growths arise from uncontrolled but lack the aggressive characteristics of cancer, such as rapid proliferation or genetic instability leading to . Benign tumors can occur in various tissues and organs, with common examples including fibroids (in the ), adenomas (in glands like the colon), and osteochondromas (on bones). Although generally harmless, larger tumors may cause issues by pressing on nearby structures. Most do not require treatment unless symptomatic, and they rarely become cancerous or recur after removal.

Definition and characteristics

Definition

A benign tumor is a non-cancerous formed by abnormal that remains localized and does not invade adjacent tissues or spread to distant parts of the body through . Unlike malignant tumors, which exhibit invasive and metastatic behavior, benign tumors are typically encapsulated and pose less threat to life, though they may cause issues if they compress nearby structures. The term "benign" derives from the Latin benignus, meaning "kind," "gentle," or "well-produced," reflecting its historical connotation of a mild or non-harmful condition in . This usage emerged prominently in the as advancements in and allowed clinicians to distinguish non-cancerous growths from malignant ones based on cellular and structural characteristics. Benign tumors differ from normal tissue growths such as , which involves an increase in the number of normal-appearing cells in response to a stimulus, without forming a discrete neoplastic mass. They also contrast with pseudotumors, which are non-neoplastic lesions that mimic tumors on or clinically but arise from inflammatory, infectious, or reactive processes rather than abnormal cellular proliferation. Representative examples of benign tumors include uterine fibroids (leiomyomas), which are common growths in the muscular wall of the , and colonic polyps, such as adenomatous polyps that project from the mucosal lining.

Key features

Benign tumors are characterized by encapsulated growth, featuring well-defined borders that separate the tumor mass from surrounding normal tissues, often forming a fibrous capsule or pseudocapsule due to compression of adjacent . This encapsulation prevents infiltration into nearby structures, resulting in a non-invasive expansile growth pattern where the tumor pushes against rather than invades adjacent tissues. Their growth rate is typically slow and progressive, which allows for adequate vascularization and minimizes ischemic damage. Histologically, benign tumors consist of well-differentiated cells that closely resemble the parent tissue of origin, maintaining organized with uniform cell size, shape, and low nuclear pleomorphism. Mitotic activity is infrequent and features normal mitotic figures without atypical forms, reflecting controlled proliferation. is typically absent or minimal, as the slow growth supports sufficient blood supply to the tumor cells. Unlike malignant tumors, benign neoplasms do not exhibit distant , remaining localized to their site of origin throughout their course. However, due to their potential for gradual enlargement, they can exert local compressive effects on nearby structures, leading to symptoms depending on location and size, such as or .

Benign versus malignant tumors

Behavioral differences

Benign tumors exhibit a localized growth behavior, remaining confined to their original site without the ability to metastasize to distant parts of the body, in contrast to malignant tumors that can spread via the bloodstream or . This non-invasive nature stems from the inherent of benign neoplasms, which do not acquire the genetic alterations necessary for detachment, migration, and establishment of secondary tumors. In terms of growth patterns, benign tumors typically expand expansively, pushing surrounding tissues aside rather than infiltrating and destroying them, which allows for a well-defined boundary and often enables complete surgical removal. Malignant tumors, however, display an infiltrative growth that disrupts adjacent structures, leading to tissue and potential complications from local destruction. Following complete excision, benign tumors have a low potential for recurrence, usually not regrowing if all abnormal tissue is removed, whereas malignant tumors frequently recur due to microscopic residual cells or metastatic deposits. Benign tumors generally do not produce systemic effects such as —a wasting syndrome involving severe , , and metabolic disturbances—unlike malignant tumors that can trigger widespread physiological disruptions through release and metabolic reprogramming. Instead, any symptoms from benign tumors arise primarily from , such as compression of nearby organs or nerves, causing localized issues like or functional impairment without broader host debilitation. For instance, fibroadenomas of the , common benign tumors composed of glandular and stromal tissue, remain confined and mobile within the breast tissue, often presenting as painless lumps without invasion, in stark contrast to invasive ductal , a malignant tumor that infiltrates surrounding breast and has a high risk of .

Structural differences

Benign tumors exhibit well-differentiated cells that closely resemble the normal tissue from which they arise, maintaining typical cellular and function, whereas malignant tumors display , characterized by poorly differentiated cells with marked pleomorphism (variation in size and shape) and hyperchromasia (increased nuclear staining due to condensed ). This lack of differentiation in malignant cells often includes abnormal nuclear features such as prominent nucleoli and a high nucleus-to-cytoplasm , distinguishing them histologically from the mature, uniform cells of benign tumors. In terms of organization, benign tumors are typically structured in orderly patterns that mimic the tissue of origin, often forming encapsulated masses with pushing borders that compress rather than infiltrate surrounding tissues. Malignant tumors, by contrast, show disorganized cellular arrangements with infiltrative growth patterns, lacking encapsulation and exhibiting irregular, stellate borders that invade adjacent structures. Mitotic figures in benign tumors are rare and, when present, appear normal and evenly distributed, reflecting controlled proliferation. In malignant tumors, mitoses are frequent, atypical (e.g., multipolar or asymmetric), and often associated with high proliferative indices, serving as a key indicator of aggressive . Regarding vascularity and stroma, benign tumors generally have blood vessels and supportive stroma similar to normal tissue. Malignant tumors, however, promote robust through the secretion of growth factors, resulting in a rich, irregular vascular network essential for their rapid expansion, alongside desmoplasia—a fibrotic stromal reaction that creates a dense, desmoplastic environment often seen in invasive carcinomas. These structural features form the basis of key diagnostic criteria in texts, such as those outlined in Robbins Basic Pathology, where combinations of differentiation, organization, mitotic activity, and stromal changes are evaluated to distinguish benign from malignant neoplasms; similarly, WHO tumor classifications incorporate these histological parameters for specific organ systems to guide accurate categorization.

Causes and risk factors

Genetic factors

Benign tumors can arise from inherited genetic syndromes involving germline mutations that predispose individuals to multiple hamartomatous or polypoid growths. PTEN hamartoma tumor syndrome, caused by germline mutations in the PTEN gene, is characterized by the development of multiple hamartomas, which are disorganized benign growths of normal tissues, affecting various organs including the skin, mucosa, and thyroid. Familial adenomatous polyposis results from germline mutations in the APC gene on chromosome 5q21-22, leading to the formation of hundreds to thousands of adenomatous colonic polyps that are initially benign but carry a high risk of progression if untreated. Tuberous sclerosis complex, due to mutations in TSC1 or TSC2 genes, manifests with benign tumors such as facial angiofibromas, which are vascular hamartomas appearing as reddish papules on the central face in most affected individuals. Von Hippel-Lindau disease, stemming from germline VHL gene mutations, is associated with the growth of hemangioblastomas, benign vascular tumors primarily in the brain, spinal cord, and retina. In addition to hereditary syndromes, somatic mutations acquired during life contribute to benign tumor formation by promoting uncontrolled without inducing . Activating mutations in RAS oncogenes, such as those in , , or NRAS, drive benign vascular proliferations like pyogenic granulomas and other vascular tumors by enhancing signaling through the RAS-RAF-MEK-ERK pathway, leading to increased and . Certain chromosomal abnormalities, including aneuploidies and structural rearrangements, are recurrent in specific benign tumors and may initiate their development. For instance, trisomy 12 is a characteristic finding in ovarian tumors and fibromas, where the extra contributes to abnormal in these hormone-producing benign neoplasms. Translocations, such as t(12;14)(q14-15;q23-24), are commonly observed in uterine leiomyomas, disrupting genes like HMGA2 and leading to overexpression that promotes smooth muscle cell growth in these frequent benign uterine tumors. In sporadic cases of benign tumors, which lack a clear hereditary pattern, polygenic influences involving multiple common genetic variants contribute to susceptibility. Polygenic risk scores derived from genome-wide association studies have been shown to predict the incidence and progression of , a common non-cancerous enlargement of the , by aggregating the effects of numerous low-penetrance alleles that modulate prostate growth pathways.

Environmental and other factors

Hormonal factors play a significant role in the development of certain benign tumors, particularly those responsive to sex steroids or growth-promoting hormones. Uterine fibroids, also known as leiomyomas, are strongly influenced by , which promotes their growth through stimulation of cell in the ; this is evident in their regression during or with anti-estrogen therapies. Similarly, excess in , caused by pituitary adenomas, increases the risk of benign tumors such as skin tags and colonic polyps by enhancing tissue overgrowth and cellular hyperplasia. Chronic irritation and inflammation contribute to the formation of benign epithelial tumors, often through repeated mechanical stress or infectious agents that trigger hyperproliferative responses. papillomas, for instance, frequently arise from human papillomavirus (HPV) infection, where viral oncoproteins disrupt epithelial cell regulation, leading to wart-like growths; low-risk HPV types are particularly associated with benign cutaneous and mucosal lesions. Additionally, friction-induced irritation in areas like the neck, , or can promote acrochordons (skin tags), benign fibroepithelial polyps resulting from localized dermal due to ongoing mechanical trauma. Ionizing radiation exposure, such as from therapeutic radiotherapy, is a well-established environmental risk for inducing benign tumors, primarily through DNA damage that favors clonal expansion of altered cells. Post-radiotherapy meningiomas, for example, develop in the following cranial irradiation for conditions like , with latency periods often exceeding 10-20 years; these tumors exhibit slow growth and are histologically benign despite their radiation-induced origin. While higher doses elevate risks, even low-dose exposures have been linked to such secondary benign neoplasms in irradiated fields. Age and sex predispositions influence the incidence of various benign tumors, reflecting cumulative environmental exposures and physiological changes over time. Lipomas, common subcutaneous adipose tumors, show a higher in middle-aged men (typically 40-60 years), possibly due to androgen-related fat differences, with males exhibiting a slight overall predominance compared to females. Other examples include uterine fibroids, which peak in reproductive-age women due to exposure. Iatrogenic factors, particularly surgical interventions, can precipitate benign tumors through aberrant or tissue implantation. Keloids, hypertrophic scars extending beyond the original site, form as benign fibrous overgrowths after procedures like cesarean sections or earlobe piercings, driven by excessive deposition in genetically susceptible individuals subjected to surgical trauma. Desmoid tumors (), though locally invasive, are often iatrogenic in non-hereditary cases, arising in surgical scars—such as abdominal walls post-colectomy—due to fibroblastic proliferation triggered by operative manipulation.

Pathophysiology

Growth mechanisms

Benign tumors arise primarily from dysregulated driven by an imbalance between and , where mitotic activity exceeds without the full activation of oncogenic pathways seen in more aggressive growths. This deregulation often stems from disruptions in homeostatic signaling within stem or cells, leading to uncontrolled clonal expansion while maintaining tissue-specific differentiation. For instance, in genes such as PTEN can impair regulatory mechanisms, resulting in excessive and reduced in affected cells. Stem cell involvement plays a central role in the origin and growth of benign tumors, with many initiating from mutated progenitor cells that fail to respond properly to niche signals. In tissues like the colon, Lgr5+ intestinal stem cells harboring mutations, such as in the Apc gene, drive the formation of adenomas through biased clonal competition and sustained proliferation. These progenitor-derived tumors expand locally by leveraging altered self-renewal pathways, such as those involving Notch signaling, without progressing to invasive states. Genetic factors, like loss-of-function mutations in tumor suppressors, serve as initial triggers for this stem cell deregulation. Angiogenesis in benign tumors is typically limited compared to malignant tumors, with new vessel formation occurring minimally to supplement nutrient supply beyond simple from surrounding tissues. Unlike scenarios requiring extensive vascularization for rapid expansion, benign growth relies primarily on passive augmented by sparse vessels, and insufficient can lead to central or if the tumor outgrows its supply. This restrained vascular response helps maintain the tumor's localized, non-invasive nature. Interactions with the (ECM) further influence benign tumor growth, particularly through -mediated encapsulation that confines the lesion. growth factors (FGFs), such as FGF-2, promote stromal activation and ECM remodeling, contributing to the formation of a fibrous capsule around the tumor mass. This process involves the deposition of and other matrix components by activated fibroblasts, which limits tumor invasion into adjacent tissues while supporting structural integrity. Hormonal and signaling pathways are key drivers in specific benign tumors, exemplified by insulin-like -1 (IGF-1) in pituitary adenomas. IGF-1 binds to its receptor on tumor cells, activating downstream pathways like ERK, Akt, and p70S6K, which enhance progression via upregulation of cyclins D1 and D3, thereby inducing proliferation. In non-functioning pituitary adenomas, IGF-1 increases cell viability by 20-40%, highlighting its in sustaining tumor expansion through mitogenic signaling.

Tumor progression

Most benign tumors reach a stable phase after initial growth, where proliferation slows or plateaus due to preserved internal regulatory mechanisms, such as intact pathways and cell-cycle checkpoints that prevent uncontrolled expansion. Unlike malignant tumors, these neoplasms typically remain localized without invading surrounding tissues, allowing them to persist for years without further progression unless disrupted by external or genetic factors. This stability underscores the non-aggressive nature of benign lesions, which often respond well to surgical intervention if symptomatic. Although rare, some benign tumors can undergo or progression to , leading to through the accumulation of additional genetic alterations. For instance, osteochondromas, common benign tumors, carry a low risk of evolving into secondary chondrosarcomas, with transformation rates estimated at less than 1% for solitary lesions and 3-5% in cases of . Such changes are marked by morphological shifts, like increased cartilage cap thickness beyond 2 cm in adults, and are more likely in sessile variants or those with EXT1 mutations. In the context of multistage carcinogenesis, benign tumors represent an early, non-invasive stage lacking the complete set of genetic "hits" required for , as exemplified by the Vogelstein model for colorectal tumorigenesis. In this framework, initial mutations in genes like lead to benign adenomatous polyps, which may remain stable for 10-35 years until subsequent alterations in , DCC, or TP53 enable and . Similarly, in the serrated pathway, BRAF mutations initiate benign hyperplastic polyps that progress only with further epigenetic changes like CpG island methylator phenotype. Factors promoting progression from benign to malignant states include chronic irritation or , which fosters a microenvironment conducive to DNA damage and mutagenesis, and the acquisition of additional somatic mutations that impair tumor suppressor functions. Chronic , implicated in approximately 25% of cancers, drives this shift by upregulating cytokines and growth factors that enhance cell survival and proliferation. For high-risk benign tumors like villous adenomas, which harbor a 10-20% risk when exceeding 2 cm, regular monitoring is essential to detect early progression. Guidelines recommend surveillance every 3 years for patients with villous features, high-grade , or multiple adenomas to facilitate timely intervention.

Types and classification

Classification systems

The classification of benign tumors has evolved significantly since the , when , the founder of cellular , introduced a tissue-based typing system emphasizing the cellular origin of tumors and their similarity to normal tissues. Virchow's seminal works, such as Die krankhaften Geschwülste (1863–1867), laid the groundwork by categorizing tumors histologically into types resembling epithelial, connective, or other tissues, distinguishing benign growths from malignant ones based on non-invasive behavior and organized structure. Over time, this morphological approach has incorporated molecular and genetic insights; for instance, the integration of genetic profiling in classifications since the early has refined subtypes by identifying specific mutations, enhancing diagnostic precision while building on Virchow's foundational cellular framework. The (WHO) provides the primary standardized taxonomic framework for benign tumors through its Classification of Tumours series (Blue Books), organizing them by and tissue of origin, with benign subtypes delineated based on histological differentiation. Benign tumors are grouped into categories such as epithelial (e.g., adenomas from glandular tissues), mesenchymal (e.g., from or fibromas from fibroblasts), and others like neural or melanocytic, emphasizing their resemblance to normal adult tissues without invasive potential. Recent editions, such as the 2020 update for and tumors and the 2025 volume for skin tumours, incorporate intermediate categories for locally aggressive benign lesions and highlight molecular markers to subtype entities like of ; the 6th edition work commenced in 2024. In clinical and epidemiological contexts, the , 11th Revision (), assigns specific codes to benign neoplasms under Chapter 2 (Neoplasms), using a structure that denotes organ location with a behavior qualifier (/0 for benign). For example, benign neoplasms of the , oral cavity, or are coded as 2E90, while those of digestive organs fall under 2E92, and endocrine glands under 2E93, facilitating standardized reporting and excluding mesenchymal-origin tumors coded separately (e.g., 2F70 for ). This system improves on prior versions by integrating morphology codes and for better data tracking. Distinctions between strictly benign tumors and borderline lesions address cases with potential for progression, such as (ADH) in the , classified as a high-risk proliferative lesion rather than fully benign. In WHO frameworks, borderline categories (e.g., B3 lesions in ) include ADH, which exhibits partial features of —such as cytologic but limited extent (≤2 mm or <2 duct spaces)—conferring a 4- to 5-fold increased risk of invasive cancer without obligate progression. These lesions are managed with surveillance or excision due to their intermediate behavior, bridging benign and premalignant states. Classification systems face limitations, particularly with mixed tumors that exhibit components from multiple tissue types, leading to overlap and diagnostic ambiguity. For instance, pleomorphic adenoma (benign mixed tumor) of salivary glands combines epithelial and mesenchymal elements, resulting in heterogeneous histology that challenges precise categorization under pure tissue-based schemes and increases recurrence risk (1-5%) if incompletely excised. Such overlaps necessitate multimodal diagnostics, including molecular testing, to resolve ambiguities, though current systems still rely heavily on morphology, potentially underestimating progression potential in hybrid lesions.

Common types by location

Benign tumors of the skin and soft tissues are among the most frequently encountered neoplasms, with lipomas representing the most common type, comprising approximately 30% of all soft tissue tumors and arising from adipose tissue as slow-growing, subcutaneous masses. Fibromas, derived from connective tissue fibroblasts, often present as firm, dermal or subcutaneous nodules, particularly in areas like the trunk and extremities, and include variants such as dermatofibromas that are prevalent in adults. Hemangiomas, vascular tumors composed of proliferated endothelial cells forming capillary or cavernous structures, commonly occur in the skin and superficial soft tissues, especially in children, and account for a significant portion of benign vascular lesions. Breast fibroadenomas, another prevalent soft tissue tumor, feature well-circumscribed mixtures of glandular and stromal elements, with recent molecular insights identifying PIK3CA mutations in a subset, as incorporated in post-2020 WHO classifications. In bone, osteochondromas are the most common benign tumors, characterized by a stalk-like exophytic growth with a cartilaginous cap continuous with the medullary cavity, typically affecting long bones in adolescents and young adults. Enchondromas arise as intramedullary cartilaginous neoplasms within the bone marrow, often in small tubular bones of the hands and feet, and are generally asymptomatic unless fractured. Giant cell tumors, while benign, exhibit locally aggressive behavior with multinucleated giant cells and stromal elements, predominantly involving the epiphysis of long bones like the knee in young adults. The 2020 WHO classification refines these entities with updated histopathological and molecular criteria for precise differentiation. Gastrointestinal benign tumors include colonic polyps, which are frequently hyperplastic—overgrowths of mucosal epithelium—or adenomatous, glandular proliferations that may project into the lumen and constitute the majority of benign colonic lesions. Leiomyomas, smooth muscle tumors, are common in the stomach and intestines, presenting as intramural or submucosal masses, with gastric leiomyomas being particularly prevalent among mesenchymal tumors. Endocrine benign tumors encompass thyroid adenomas, follicular or macrofollicular proliferations of thyroid epithelium forming nodules, which are the most common thyroid neoplasms and often discovered incidentally. Pituitary prolactinomas, prolactin-secreting adenomas arising from lactotroph cells, represent the most frequent functional pituitary tumors, typically microadenomas under 10 mm in size. In the gynecological system, uterine fibroids, also known as leiomyomas, are the most prevalent benign tumors, consisting of smooth muscle cells and fibrous connective tissue within the myometrium, affecting up to 70% of women by menopause.

Clinical presentation

General signs

Benign tumors often present with minimal or no symptoms, as they grow slowly and remain localized without invading surrounding tissues. Many are discovered incidentally during imaging studies for unrelated conditions, such as routine scans or evaluations for other health issues. For instance, small benign growths in organs like the or adrenal glands may remain asymptomatic throughout life unless they reach a size that impacts nearby structures. When symptoms do occur, they typically arise from the physical presence of the tumor, known as mass effect, where the growth compresses adjacent tissues, nerves, or organs. This can manifest as a palpable lump or swelling in superficial locations, such as the skin or subcutaneous tissue, or more subtle organ dysfunction in deeper sites. Pain, if present, is usually a dull ache resulting from the stretching of surrounding tissues or capsule rather than inflammation or rapid growth. Unlike malignant tumors, benign ones rarely cause acute or severe pain unless significant compression occurs. Functional impairment can also result from mass effect, leading to localized disruptions in normal bodily functions. Examples include bowel obstruction due to colonic polyps compressing the intestinal lumen or vision disturbances from orbital tumors pressing on optic structures. These effects are directly tied to the tumor's size and position rather than its biological activity. Benign tumors generally lack the systemic manifestations seen in malignancies, such as fever, unexplained weight loss, or paraneoplastic syndromes from metastasis, as they do not trigger widespread immune responses. However, functional benign tumors, particularly in endocrine glands, may cause systemic symptoms due to hormone secretion, such as acromegaly from pituitary adenomas. Site-specific symptoms, such as those varying by organ involvement, are addressed separately.

Site-specific symptoms

Benign tumors in the head and neck region can produce symptoms related to local compression or irritation of nearby structures. Thyroid nodules, which are often benign such as colloid nodules or follicular adenomas, may cause dysphagia due to esophageal compression or hoarseness from recurrent laryngeal nerve involvement, particularly when the nodule is large or located posteriorly. Pleomorphic adenomas of the salivary glands, the most common benign tumor in this area, typically present as a slowly enlarging, painless swelling in the parotid or submandibular region, leading to facial asymmetry or visible mass effect without significant pain unless secondarily infected. In the breast, fibroadenomas are the predominant benign tumors, manifesting as painless, well-defined, mobile lumps that are rubbery on palpation and typically discovered during self-examination or routine screening. These masses may become tender or more prominent during lactation, potentially causing localized discomfort or milk discharge if they obstruct ducts, though most remain asymptomatic beyond the palpable lump. Abdominal and pelvic benign tumors often arise from reproductive or hepatic tissues, with symptoms stemming from mass effect on adjacent organs. Uterine fibroids (leiomyomas) frequently lead to menorrhagia, characterized by heavy or prolonged menstrual bleeding, and urinary frequency due to bladder compression, especially with submucosal or intramural growths that distort the uterine cavity. In contrast, hepatic hemangiomas, the most common benign liver tumors, are typically silent and asymptomatic, discovered incidentally on imaging, though larger lesions may rarely cause right upper quadrant pain from capsular stretch. Benign tumors in the extremities commonly involve soft tissue or bone, presenting with localized mechanical symptoms. Lipomas, benign fatty tumors, appear as soft, subcutaneous nodules that are mobile under the skin and usually painless, though they may cause cosmetic concerns or discomfort if pressing on nerves. In the upper limb, benign soft tissue tumors such as schwannomas or neurofibromas can compress nerves or blood vessels, leading to pain, numbness, tingling, or weakness and movement issues in the arm. Benign bone tumors, such as osteoid osteomas, often cause localized pain (typically nocturnal and relieved by NSAIDs) due to periosteal irritation, while non-ossifying fibromas are usually asymptomatic but may present with pathologic fracture in long bones like the femur or tibia; swelling may accompany either. Central nervous system benign tumors, particularly meningiomas arising from the dura mater, can exert pressure on brain tissue or cranial nerves, resulting in site-specific neurological deficits. These may include chronic headaches from increased intracranial pressure or seizures due to cortical irritation, with symptoms varying by location such as visual disturbances from optic nerve compression in sellar meningiomas.

Diagnosis

Imaging techniques

Imaging techniques play a crucial role in the initial detection, localization, and characterization of benign tumors, allowing clinicians to assess size, location, and features suggestive of benignity without invasive procedures. These modalities help differentiate benign lesions from malignant ones based on characteristics such as well-defined margins, lack of invasion, and specific signal intensities, often guiding the decision for further histopathological confirmation. Ultrasound serves as the first-line imaging modality for evaluating superficial soft-tissue masses due to its accessibility, lack of radiation, and real-time capabilities. It is particularly effective for characterizing lesions like lipomas, which typically appear as well-defined, hyperechoic masses with possible thin hypoechoic septations, exhibiting good sensitivity and specificity in diagnosis. For other superficial benign tumors, such as epidermal cysts or pilomatricomas, ultrasound reveals homogeneous or heterogeneous echotexture with clear borders, aiding in distinguishing them from more aggressive processes. For deeper soft-tissue or visceral benign tumors, magnetic resonance imaging (MRI) and computed tomography (CT) provide superior anatomical detail and are preferred for preoperative planning. MRI excels in delineating tumor extent and tissue characteristics, with benign fibroids (uterine leiomyomas) often showing T2-hyperintense signals in degenerated variants and variable contrast enhancement patterns that are typically homogeneous and less aggressive than in malignancies. CT is valuable for bony involvement or calcifications, offering cross-sectional views to confirm non-invasive, well-circumscribed lesions in deep-seated tumors like schwannomas. Plain X-ray radiography remains a fundamental tool for initial assessment of bone-related benign tumors, revealing characteristic features such as well-defined, corticated margins and lack of periosteal reaction. For instance, enchondromas or non-ossifying fibromas appear as geographic lytic lesions with sclerotic borders, helping to rule out aggressive bone destruction. This modality is cost-effective and widely available but is often supplemented by advanced imaging for confirmation. Positron emission tomography (PET), usually combined with CT, has limited utility in benign tumor evaluation due to the generally low fluorodeoxyglucose (FDG) uptake in these lesions compared to malignant counterparts. Benign tumors exhibit FDG avidity similar to surrounding normal tissues, with standardized uptake values (SUV) typically below 2.5, making PET more useful for excluding metastasis in suspected cases rather than primary diagnosis. False positives can occur in inflammatory benign processes, necessitating correlation with other modalities. Recent advances in artificial intelligence (AI)-assisted imaging, particularly post-2020, enhance the differentiation of benign from malignant tumors across modalities like ultrasound, MRI, and CT. Machine learning models, such as convolutional neural networks applied to radiomic features, achieve high accuracy (e.g., AUC >0.90) in classifying soft-tissue and lesions by analyzing texture and enhancement patterns, reducing diagnostic variability and supporting non-invasive . These tools, validated in studies on uterine fibroids and bone tumors, integrate with clinical workflows to improve specificity in challenging cases.

Histopathological confirmation

Histopathological confirmation of a benign tumor typically follows initial studies to obtain tissue for definitive diagnosis. This process involves procedures that sample the , allowing pathologists to examine cellular and architectural features under a microscope. Common types include (FNA), which uses a thin needle to extract cells for cytological analysis; core needle , which obtains a larger tissue core for histological evaluation; and excisional , which removes the entire or a significant portion for comprehensive assessment, particularly useful for superficial or accessible tumors. Microscopic evaluation focuses on key features that distinguish benign tumors from malignant ones, including well-circumscribed margins without into surrounding tissues, relatively low stromal cellularity, and absence of nuclear such as pleomorphism or hyperchromasia. In benign lesions like phyllodes tumors of the breast, the stroma shows mild hypercellularity with minimal to no and pushing borders, contrasting with the infiltrative growth and high-grade seen in sarcomas. These characteristics confirm the non-invasive, organized growth pattern typical of benign neoplasms. Immunohistochemistry (IHC) enhances diagnostic accuracy by detecting specific protein markers. For instance, Ki-67, a proliferation index, is typically low (often <5%) in benign tumors, indicating minimal , whereas higher indices suggest . Markers like S100 are positive in benign neural-derived tumors such as granular cell tumors, supporting their schwannian origin alongside other stains like CD68. In borderline or atypical cases, molecular testing may be employed to clarify the benign nature. For melanocytic lesions, BRAF V600E mutations are common in both benign nevi (up to 80% of cases) and melanomas, but their presence alone does not distinguish ; instead, they aid in ruling out progression when combined with . Such testing is particularly useful in equivocal spitzoid neoplasms to assess risk without overdiagnosing benign entities. Diagnostic pitfalls arise when benign tumors mimic malignancy or vice versa, such as reactive simulating due to follicular proliferation and atypia-like changes in lymph nodes. Other mimics include pseudoneoplastic lesions like inflammatory pseudotumors, which exhibit spindle cell proliferation resembling but lack true neoplastic . There is also a rare risk of benign tumors being initially misdiagnosed as malignant based on imaging or clinical features, necessitating confirmatory procedures such as biopsy or advanced imaging like MRI or ultrasound. Careful correlation with clinical context and ancillary tests is essential to avoid misdiagnosis.

Management and treatment

Surgical options

Surgical excision remains the cornerstone of treatment for most benign tumors, particularly when they cause symptoms, grow progressively, or pose risks to adjacent structures. This approach aims for complete removal to prevent recurrence, often involving en bloc resection with clear margins around the tumor capsule to ensure no residual tissue remains. For encapsulated benign tumors such as , enucleation—a technique where the tumor is shelled out intact after incising the overlying — is commonly employed, minimizing disruption to surrounding healthy tissue. Minimally invasive techniques have become standard for accessible benign tumors, reducing recovery time and postoperative pain compared to open . Laparoscopic myomectomy, for instance, is widely used for uterine fibroids (leiomyomas), involving small abdominal incisions through which instruments remove the fibroids while preserving the . Similarly, endoscopic polypectomy or mucosal resection effectively treats gastrointestinal polyps, such as colonic adenomas, by snaring or lifting and resecting the lesion via a flexible , often during routine . In orthopedic contexts, is the preferred method for intraosseous benign tumors like enchondromas, where the surgeon scrapes out the cartilaginous from the bone cavity using specialized instruments, sometimes followed by to support healing. All surgical interventions carry inherent risks, including bleeding, at the surgical site, and complications from such as allergic reactions or respiratory issues, with rates varying by tumor location and patient factors. Advancements in robotic-assisted surgery have enhanced precision for complex benign tumor resections, particularly in confined spaces like the or retroperitoneum, with widespread adoption by the early due to improved visualization and maneuverability. For example, robotic myomectomy allows for meticulous dissection of large fibroids with reduced blood loss. In cases where tumors are asymptomatic and stable, surgical options may be deferred in favor of , though intervention is recommended if growth or symptoms emerge.

Non-surgical approaches

For asymptomatic or slow-growing benign tumors that do not pose immediate risks, watchful waiting—also known as active surveillance—involves regular clinical evaluations and imaging to monitor for changes in size or symptoms without immediate intervention. This approach is particularly suitable for small pituitary adenomas less than 1 cm in diameter that are non-functioning and incidental, where serial MRI scans every 2-3 years for asymptomatic microadenomas per 2025 Pituitary Society guidelines, or more frequently (e.g., every 6-12 months initially) if clinically indicated, allow detection of growth prompting escalation to treatment. Similarly, for benign ovarian cysts confirmed as non-cancerous via ultrasound, monitoring with follow-up imaging at 6-12 month intervals reduces unnecessary surgery while ensuring safety. Pharmacotherapy targets symptom relief or tumor shrinkage in specific benign tumors without resorting to excision. (GnRH) agonists, such as leuprolide, are used for uterine fibroids (leiomyomas) in premenopausal women, inducing a hypoestrogenic state that reduces fibroid volume by 30-50% and alleviates heavy bleeding, often administered for 3-6 months to manage symptoms or prepare for procedures. For infantile hemangiomas, oral beta-blockers like serve as first-line therapy, promoting involution by and of endothelial cells, with over 90% response rates in proliferating lesions, typically dosed at 1-3 mg/kg/day for 3-6 months. Radiation therapy is reserved rarely for benign tumors that are inoperable due to location or patient factors, such as skull base meningiomas, where stereotactic radiosurgery or fractionated external beam radiation achieves 90-95% local control at 5-10 years by halting cell proliferation. As of 2025, advancements in stereotactic techniques continue to improve precision and outcomes for such benign intracranial tumors. This modality is not first-line owing to potential long-term risks like secondary malignancies but is effective for residual or recurrent grade I meningiomas post-incomplete resection. Embolization provides a minimally invasive option for vascular benign tumors, such as hemangiomas or highly vascular meningiomas, by occluding feeding arteries with embolic agents to devascularize the , which can reduce its size by 50-80% in hemangiomas while facilitating symptom control or safer subsequent interventions for highly vascular tumors like meningiomas. Professional guidelines emphasize tailored monitoring: The American College of Obstetricians and Gynecologists (ACOG) recommends for asymptomatic uterine fibroids with annual pelvic exams and imaging as needed based on symptom progression, while the (NCCN) advises MRI surveillance every 6-12 months for stable grade I meningiomas to assess growth. If symptoms worsen, escalation to more definitive management may be considered.

Prognosis and complications

Long-term outcomes

Benign tumors generally carry an excellent , with near-100% long-term rates due to their non-metastatic , and complete surgical removal achieves a cure in the vast majority of cases. Recurrence rates following incomplete excision are typically low at 5-10% across most benign tumors, though certain aggressive subtypes like desmoid tumors exhibit higher rates, as high as 50% even after wide excision. Post-treatment is minimally affected for benign tumors, with patients often returning to normal activities without significant impairment; for uterine fibroids, fertility-preserving options like myomectomy maintain reproductive potential and enhance overall well-being. Routine follow-up imaging, such as MRI or , is advised at 6-12 months after treatment to assess for any residual or recurrent disease, with subsequent surveillance tailored to the tumor type and initial response. Epidemiologically, benign tumors vary widely in incidence; for instance, osteochondromas, one of the most common benign tumors accounting for 20-50% of such cases, have a of about 1 in 50,000 for the variant.

Potential risks

Although benign tumors do not invade surrounding tissues or spread to distant sites like malignant tumors, they can still present significant health risks primarily through their local growth and effects on nearby structures. Large benign tumors may compress adjacent organs, , or vessels, leading to symptoms such as , , or impaired function; for instance, in the chest can press on the windpipe, heart, or lungs, potentially causing breathing difficulties or cardiovascular issues. Such compression on nerves can specifically result in numbness or impaired movement and weakness in the affected area, particularly in cases of benign soft tissue tumors in extremities. In the , benign tumors like meningiomas can grow to exert pressure on neural tissue, resulting in headaches, seizures, vision changes, or cognitive impairments if left untreated. Certain benign tumors, particularly those in endocrine organs, can disrupt hormone production and cause systemic effects. Adrenal adenomas, for example, may secrete excess or aldosterone, leading to conditions like or , which increase risks of and metabolic disorders if not managed. Similarly, pituitary adenomas can overproduce hormones such as or , potentially causing , , or other endocrine imbalances that affect overall health. Hemorrhagic complications represent another risk, especially in vascular or friable benign tumors. Uterine fibroids (leiomyomas) can cause or due to their proximity to the uterine lining, while hepatic adenomas carry a notable risk of rupture and , particularly if larger than 5 cm, occurring in approximately 25% of cases. In the liver, such bleeding may require emergency intervention like or . Although rare, some benign tumors have the potential for , altering their prognosis. Hepatocellular adenomas, for instance, exhibit a 5-6% risk of progressing to , with higher rates in males or tumors exceeding 5 cm; certain subtypes, like β-catenin-activated adenomas, elevate this risk further. Colonic adenomas also demonstrate a propensity for malignant change, underscoring the importance of removal during screening to prevent development. Skull base tumors, even when benign, can endanger life by compressing critical structures like tissue or major vessels, potentially leading to sudden neurological deterioration. Untreated growth of benign tumors can exacerbate these risks over time, impacting through , functional limitations, or secondary complications like infections from obstructed pathways. For tumors such as osteochondromas, continued expansion may lead to fractures or impingement, while chest tumors can cause respiratory compromise if they enlarge significantly. Overall, while most benign tumors remain and non-life-threatening, their location, size, and type determine the severity of potential risks, often necessitating vigilant monitoring or intervention.

References

  1. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/benign-tumor
  2. https://www.msdmanuals.com/home/cancer/overview-of-cancer/overview-of-cancer
  3. https://www.cedars-sinai.org/blog/diagnosed-with-benign-tumor.html
  4. https://medlineplus.gov/benigntumors.html
  5. https://www.merriam-webster.com/dictionary/benign
  6. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.26320
  7. https://training.seer.cancer.gov/disease/cancer/terms.html
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC11135271/
  9. https://my.clevelandclinic.org/health/diseases/9130-uterine-fibroids
  10. https://www.mayoclinic.org/diseases-conditions/colon-polyps/symptoms-causes/syc-20352875
  11. https://www.ncbi.nlm.nih.gov/books/NBK9553/
  12. https://pubmed.ncbi.nlm.nih.gov/21326014/
  13. https://www.sciencedirect.com/topics/medicine-and-dentistry/benign-tumor
  14. https://my.clevelandclinic.org/health/diseases/22121-benign-tumor
  15. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC4037932/
  17. https://seer.cancer.gov/tools/mphrules/2007_mphrules_manual_08242012.pdf
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3684701/
  19. https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/understanding-your-pathology-report/breast-pathology/benign-breast-conditions-pathology.html
  20. https://pathology.oit.duke.edu/siteParts/avaps/02.22.1_Neoplasia_I_Final.pdf
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7905527/
  22. https://webpath.med.utah.edu/NEOHTML/NEOPL108.html
  23. https://tumourclassification.iarc.who.int/
  24. https://www.ncbi.nlm.nih.gov/books/NBK1488/
  25. https://www.ncbi.nlm.nih.gov/books/NBK538233/
  26. https://www.ncbi.nlm.nih.gov/books/NBK1220/
  27. https://www.ncbi.nlm.nih.gov/books/NBK1463/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC4430357/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC1886274/
  30. https://pubmed.ncbi.nlm.nih.gov/7533530/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC11110300/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC3914832/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10300720/
  34. https://www.ncbi.nlm.nih.gov/books/NBK560737/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4961504/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3356990/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4984935/
  38. https://www.ncbi.nlm.nih.gov/books/NBK507906/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7940466/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7693298/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC9612571/
  42. https://doi.org/10.1126/science.1224676
  43. https://www.creative-diagnostics.com/angiogenesis-and-cancer.htm
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC3664927/
  45. https://doi.org/10.1016/j.mce.2014.04.007
  46. https://www.ncbi.nlm.nih.gov/books/NBK26891/
  47. https://www.ncbi.nlm.nih.gov/books/NBK26902/
  48. https://www.ncbi.nlm.nih.gov/books/NBK544296/
  49. https://pubmed.ncbi.nlm.nih.gov/2188735/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC6981255/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC8432987/
  52. https://www.ncbi.nlm.nih.gov/books/NBK470272/
  53. https://www.sciencedirect.com/science/article/pii/S0344033888801389
  54. https://pubmed.ncbi.nlm.nih.gov/3047716/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC8305942/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC7509695/
  57. https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC9758819/
  60. https://www.findacode.com/icd-11/block-164118119.html
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8720406/
  62. https://www.pathologyoutlines.com/topic/breastadh.html
  63. https://insightsimaging.springeropen.com/articles/10.1186/s13244-021-01005-6
  64. https://www.ncbi.nlm.nih.gov/books/NBK564295/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC10562281/
  66. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/mixed-tumor
  67. https://schaberg.faculty.ucdavis.edu/wp-content/uploads/sites/604/2025/02/Soft-Tissue-tumors.pdf
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4253162/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC6536971/
  70. https://www.hss.edu/health-library/conditions-and-treatments/list/benign-bone-tumor
  71. https://health.uconn.edu/orthopedics-sports-medicine/conditions-and-treatments/a-z-index/benign-malignant-tumors/
  72. https://www.ncbi.nlm.nih.gov/books/NBK6994/
  73. https://www.ncbi.nlm.nih.gov/books/NBK6948/
  74. https://www.ncbi.nlm.nih.gov/books/NBK65830/
  75. https://www.ncbi.nlm.nih.gov/books/NBK546680/
  76. https://www.mdpi.com/2077-0383/11/3/699
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC7506257/
  78. https://medlineplus.gov/ency/article/001310.htm
  79. https://www.mayoclinic.org/diseases-conditions/peripheral-nerve-tumors-benign/symptoms-causes/syc-20368680
  80. https://emedicine.medscape.com/article/1253816-clinical
  81. https://www.ncbi.nlm.nih.gov/books/NBK585125/
  82. https://my.clevelandclinic.org/health/diseases/21881-tumor
  83. https://www.mayoclinic.org/diseases-conditions/pituitary-tumors/symptoms-causes/syc-20350548
  84. https://pubs.rsna.org/doi/full/10.1148/rg.220085
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC3575959/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8354710/
  87. https://my.clevelandclinic.org/health/diseases/25073-pleomorphic-adenoma
  88. https://www.mayoclinic.org/diseases-conditions/parotid-tumor/symptoms-causes/syc-20578986
  89. https://www.ncbi.nlm.nih.gov/books/NBK535345/
  90. https://my.clevelandclinic.org/health/diseases/15690-fibroadenomas-of-the-breast
  91. https://www.mayoclinic.org/diseases-conditions/fibroadenoma/symptoms-causes/syc-20352752
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC6905250/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC9580818/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC6247381/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC8727199/
  96. https://www.ncbi.nlm.nih.gov/books/NBK518988/
  97. https://my.clevelandclinic.org/health/diseases/16778-benign-soft-tissue-tumors
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC8836463/
  99. https://www.ncbi.nlm.nih.gov/books/NBK537279/
  100. https://www.mayoclinic.org/diseases-conditions/meningioma/symptoms-causes/syc-20355643
  101. https://my.clevelandclinic.org/health/diseases/17858-meningioma
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC10243847/
  103. https://www.tandfonline.com/doi/full/10.2147/RMI.S54490
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC5502938/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC7441113/
  106. https://pubs.rsna.org/doi/10.1148/radiology.189.3.8234695
  107. https://emedicine.medscape.com/article/405676-overview
  108. https://radiologyassistant.nl/musculoskeletal/bone-tumors/differential-diagnosis
  109. https://www.sciencedirect.com/science/article/abs/pii/S0969805100001414
  110. https://ajronline.org/doi/10.2214/AJR.07.2083
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC12581291/
  112. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1621642/full
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC10047175/
  114. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/biopsy/art-20043922
  115. https://emedicine.medscape.com/article/1253816-workup
  116. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/biopsies
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC5027876/
  118. https://meridian.allenpress.com/aplm/article/128/7/771/458840/Granular-Cell-Tumor-Immunohistochemical-Assessment
  119. https://www.pathologyoutlines.com/topic/stainski67.html
  120. https://pubmed.ncbi.nlm.nih.gov/15214825/
  121. https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/laboratory/notifications/braf-genetic-testing-in-patients-with-melanoma-01-01-19
  122. https://deepblue.lib.umich.edu/bitstream/handle/2027.42/171197/his14570.pdf?sequence=1
  123. https://www.nature.com/articles/modpathol2012176
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC4447941/
  125. https://www.sciencedirect.com/science/article/abs/pii/S074025701500129X
  126. https://www.mayoclinic.org/diseases-conditions/lipoma/diagnosis-treatment/drc-20374474
  127. https://www.mayoclinic.org/tests-procedures/myomectomy/about/pac-20384710
  128. https://www.mayoclinic.org/medical-professionals/digestive-diseases/news/endoscopic-mucosal-resection-for-management-of-large-colorectal-polyps/mac-20442005
  129. https://my.clevelandclinic.org/health/diseases/22113-enchondroma
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC8102812/
  131. https://www.webmd.com/a-to-z-guides/benign-tumors-causes-treatments
  132. https://tischbraintumorcenter.duke.edu/blog/what-happens-if-benign-tumor-left-untreated
  133. https://www.mayoclinic.org/diseases-conditions/pituitary-tumors/diagnosis-treatment/drc-20350553
  134. https://nyulangone.org/conditions/pituitary-tumors/treatments/watchful-waiting-for-pituitary-tumors
  135. https://www.nature.com/articles/s41574-025-01134-8
  136. https://hscweb3.hsc.usf.edu/blog/2019/09/11/watchful-waiting-with-routine-ultrasound-safer-than-removing-ovarian-cysts-classified-as-noncancerous-study-suggests/
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC6485466/
  138. https://www.ogscience.org/m/journal/view.php?number=467
  139. https://medlineplus.gov/druginfo/meds/a615024.html
  140. https://pmc.ncbi.nlm.nih.gov/articles/PMC4078206/
  141. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/meningioma-treatment
  142. https://pmc.ncbi.nlm.nih.gov/articles/PMC9722800/
  143. https://pmc.ncbi.nlm.nih.gov/articles/PMC12504101/
  144. https://cco.amegroups.org/article/view/15325/html
  145. https://utswmed.org/conditions-treatments/tumor-embolization/
  146. https://www.ajnr.org/content/22/8_suppl/S14
  147. https://www.mdpi.com/2077-0383/11/16/4762
  148. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/management-of-symptomatic-uterine-leiomyomas
  149. https://droracle.ai/articles/437876/what-is-the-recommended-surveillance-protocol-for-patients-with-a-history-of-meningioma-particularly-those-with-atypical-or-malignant-meningiomas-according-to-national-comprehensive-cancer-network-nccn-guidelines
  150. https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/what-is-soft-tissue-sarcoma/non-cancerous-tumours
  151. https://consultqd.clevelandclinic.org/excellent-outcomes-achievable-with-surgical-resection-of-benign-cardiac-tumors
  152. https://pmc.ncbi.nlm.nih.gov/articles/PMC3568525/
  153. https://www.sciencedirect.com/science/article/pii/S1743919116301558
  154. https://www.fertstert.org/article/S0015-0282%2824%2900024-4/fulltext
  155. https://www.uhhospitals.org/blog/articles/2022/08/latest-fibroid-treatment-techniques-can-preserve-fertility
  156. https://ajronline.org/doi/10.2214/AJR.11.7455
  157. https://ascopost.com/issues/june-10-2013/study-clarifies-appropriate-timing-of-follow-up-imaging-after-benign-breast-biopsies/
  158. https://www.mayoclinic.org/diseases-conditions/benign-adrenal-tumors/symptoms-causes/syc-20356190
  159. https://www.mayoclinic.org/diseases-conditions/skull-base-tumors/symptoms-causes/syc-20581941
  160. https://pathology.jhu.edu/pancreas/types-of-tumors
Add your contribution
Related Hubs
User Avatar
No comments yet.